Trial
NCT04547140
Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Grifols Therapeutics LLC
Collaborators
—
Condition
COVID-19
Intervention
Liquid Alpha1-Proteinase Inhibitor (Human)
Why stopped
Study Stopped for Futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-03-22